| Kris Ferguson, MD | |
|
4131 W Loomis Rd, Suite 300, Greenfield, WI 53221-2057 | |
| (414) 325-7246 | |
| (414) 325-3770 |
| Full Name | Kris Ferguson |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 19 Years |
| Location | 4131 W Loomis Rd, Greenfield, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376751271 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspirus Riverview Hospital & Clinics Inc | Wisconsin rapids, WI | Hospital |
| Langlade Hospital | Antigo, WI | Hospital |
| Ascension St Michaels Hospital | Stevens point, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aspirus Riverview Hospital And Clinics Inc | 4587658182 | 144 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Aspirus Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669595294 PECOS PAC ID: 1052223625 Enrollment ID: O20031103000267 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Aspirus Rhinelander & Tomahawk Hospitals & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144991340 PECOS PAC ID: 9335059856 Enrollment ID: O20031126000706 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Advanced Pain Management Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770506669 PECOS PAC ID: 1456257633 Enrollment ID: O20031209000560 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Aspirus Wausau Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922321140 PECOS PAC ID: 6406757442 Enrollment ID: O20040114000297 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Langlade Hospital - Hotel Dieu Of St Joseph Of Antigo Wisconsin |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831251040 PECOS PAC ID: 1557271202 Enrollment ID: O20040212000310 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Aspirus Riverview Hospital & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295754844 PECOS PAC ID: 4587658182 Enrollment ID: O20040414000945 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Entity Name | Aspirus Stevens Point Hospital & Clinics, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538112230 PECOS PAC ID: 1850358938 Enrollment ID: O20041210000558 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kris Ferguson, MD 4131 W Loomis Rd, Suite 300, Greenfield, WI 53221-2057 Ph: (414) 325-7246 | Kris Ferguson, MD 4131 W Loomis Rd, Suite 300, Greenfield, WI 53221-2057 Ph: (414) 325-7246 |
News Archive
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
› Verified 4 days ago
Dr. Bhupinder S Saini, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 4131 W. Loomis Rd, Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Hany Radwan Nosir, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 4131 W Loomis Rd, Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Dr. Scott Aschenbrener, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 4131 W Loomis Rd, Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Dr. Mark K Aasen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4131 W. Loomis Rd, Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Dr. Dermot J. More O'ferrall, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 4131 W. Loomis Rd., Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Dr. Harry A Tagalakis, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4131 W. Loomis Rd., Ste 300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 |